Axiom Biosciences opens Wefunder round to fund Phase 2 push
What's the deal? Axiom Biosciences, a San Diego clinical-stage biotech, opened a Regulation Crowdfunding offering on Wefunder, letting eligible retail investors back its therapeutics pipeline. The company — formerly Cytonus Therapeutics — develops regenerative therapies and targeted biologic candidates. It filed the offering under Section 4(a)(6) of the Securities Act of 1933 through Wefunder Portal LLC.
What's the endgame? Axiom plans to use the proceeds to advance its pipeline, including a planned Phase 2 program, and to cover expenses tied to a possible future public listing in Hong Kong. Its lead program targets severe brain injuries in newborns, including intraventricular hemorrhage and hypoxic-ischemic encephalopathy. It is also developing technology to deliver biologic therapies directly to disease sites.
Why now? The round follows two developments this year. In July, Axiom reported positive Phase 1 results for its investigational stem-cell therapy for severe newborn brain injuries; in September, it partnered with GeneFabDealroom has a profile for this one. Try Dealroom →, a cell and gene therapy manufacturer, for development and production support.
What's next? Beyond the crowdfunding round, Axiom said it expects to run a separate private financing aimed at institutional, accredited investors, closing after the Wefunder offering wraps.
"Our Wefunder community round broadens access to investment in our company for smaller / individual investors as we advance our pipeline and prepare for a potential public listing," said founder and chief executive officer Remo Moomiaie-Qajar.
What could go wrong? The program remains early-stage, and neither the next trial nor the Hong Kong listing is secured. The announcement does not disclose the offering's size or terms.
The signal: Pairing a retail crowdfunding round with a planned institutional raise shows how clinical-stage biotechs are widening their funding mix to finance expensive trials and prepare for a listing — while the underlying science is still unproven.
Read more: startupresearcher.com
Image credit: Generated with Gemini
